Development and Validation of a Novel Prognostic Nomogram Based on Platelet and CD8(+)T Cell Counts in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis

基于血小板和CD8(+)T细胞计数的肝细胞癌门静脉肿瘤血栓患者新型预后列线图的建立与验证

阅读:2

Abstract

PURPOSE: Portal vein tumor thrombosis (PVTT) is one of the hallmarks of advanced Hepatocellular carcinoma (HCC). Platelet (PLT) function parameters and CD8(+)T cells (CD8(+)Ts) play an important role in HCC progression and metastasis. This study is committed to establishing an efficient prognosis prediction model and exploring the combined effect of PLT and CD8(+)Ts on PVTT prognosis. PATIENTS AND METHODS: This retrospective study collected 932 HCC patients with PVTT from 2007 to 2017 and randomly divided them into a training cohort (n = 656) and a validation cohort (n = 276). We performed multivariable Cox and Elastic-net regression analysis, constructed a nomogram and used Kaplan-Meier survival curves to compare overall survival and progression-free survival rates in different substrata. Relationships between indicators involved were also analyzed. RESULTS: We found tumor number, size, treatment, PLT, γ-glutamyl transferase, alpha-fetoprotein, mean platelet volume, and CD8(+)Ts were related to the 5-year OS of patients with PVTT, and established a nomogram. The area under the receiver operating characteristic curve (AUCs) for predicting the 1-year OS rates were 0.767 and 0.794 in training and validation cohorts. The calibration curve and decision curve indicated its predictive consistency and strong clinical utility. We also found those with low PLT (<100*10^9/L) and high CD8(+)Ts (>320 cells/μL) had a better prognosis. CONCLUSION: We established a well-performing prognostic model for PVTT based on platelet functional parameters and CD8(+)Ts, and found that PT-8 formed by PLT and CD8(+)Ts was an excellent predictor of the prognosis of PVTT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。